Dr. Zandberg on the Role of Durvalumab in Head and Neck Cancer
Dan Zandberg, MD, assistant professor of Medicine, the University of Maryland Medical Center, discusses the role of durvalumab (Imfinzi) in patients with metastatic head and neck cancer.
The phase II HAWK trial investigated durvalumab in patients with metastatic head and neck cancer who were PD-L1 high, states Zandberg. Promising outcomes were seen with an overall response rate (ORR) of 16% and durable response of 55%. The median overall survival was 7 months with a 1-year survival of 33%.
Related Videos
Related Content
